Literature DB >> 20533552

Chiral self assembled monolayers as resolving auxiliaries in the crystallization of valine.

Aniruddh Singh1, Allan S Myerson.   

Abstract

Chiral drugs are a subgroup of drug substances that contain one or more chiral centers. For reasons of safety and efficacy, the pure enantiomer is usually preferred over the racemate in many marketed dosage forms. Thus, resolution of racemic mixtures is an active area of research. In this work, chiral self assembled monolayers (SAMs) on gold were employed as resolving auxiliaries in the crystallization of the amino acid valine. Results showed the ability to obtain one enantiomer in excess on the crystals grown on the chiral SAMs when starting with racemic solutions. The enantiomer obtained in excess was the one having opposite chirality to the monolayer being used. In addition, it was possible to obtain crystals of the pure enantiomer when starting with a solution having an enantiomeric excess value of 50%. Control experiments carried out without chiral SAMs showed that at equilibrium, mixtures of the pure enantiomer and racemic compound were obtained under these conditions. The enantiomer obtained on the chiral SAMs was the one that was initially present in excess regardless of the chirality of the monolayer being used.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20533552     DOI: 10.1002/jps.22237

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  2 in total

1.  Rapid crystallization of glycine using metal-assisted and microwave-accelerated evaporative crystallization: the effect of engineered surfaces and sample volume.

Authors:  Tsehai A J Grell; Melissa A Pinard; Danielle Pettis; Kadir Aslan
Journal:  Nano Biomed Eng       Date:  2012

2.  Crystallization of l-alanine in the presence of additives on a circular PMMA platform designed for metal-assisted and microwave-accelerated evaporative crystallization.

Authors:  Anginelle M Alabanza; Muzaffer Mohammed; Kadir Aslan
Journal:  CrystEngComm       Date:  2012-12-21       Impact factor: 3.545

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.